for people ages 18-75 (full criteria)
at UC Davis UC Irvine UCLA UCSD
study started
estimated completion
Principal Investigator
by James Mangan, MD, PhD (ucsd)Gary Schiller, MD (ucla)Pamela Becker, MD, PhD (uci)Brian Jonas, MD (ucdavis)
Photo of James Mangan
James Mangan



This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Official Title

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia


Acute Myeloid Leukemia AML Relapsed AML Refractory AML Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Uproleselan Uproleselan (GMI-1271)


You can join if…

Open to people ages 18-75

  • ≥18 years and ≤75 years in age
  • Patients with relapsed or refractory AML
  • No more than one prior stem cell transplant
  • Has not received the chemotherapy regimen to be used for induction on this trial
  • Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

You CAN'T join if...

  • Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
  • Active signs or symptoms of CNS involvement by malignancy.
  • Stem cell transplantation ≤4 months prior to dosing.
  • Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
  • Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  • Inadequate organ function.
  • Abnormal liver function.
  • Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
  • Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
  • Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  • Clinically significant cardiovascular disease.
  • Major surgery within 4 weeks of dosing.


  • UC San Diego Moore Cancer Center accepting new patients
    La Jolla California 92093 United States
  • University of California, Los Angeles - UCLA accepting new patients
    Los Angeles California 90095 United States
  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • UC Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States

Lead Scientists at University of California Health

  • James Mangan, MD, PhD (ucsd)
    Associate Clinical Professor, Medicine. Authored (or co-authored) 30 research publications.
  • Gary Schiller, MD (ucla)
    Professor-in-Residence, Medicine. Authored (or co-authored) 77 research publications.
  • Pamela Becker, MD, PhD (uci)
    Clinical Professor, Medicine. Authored (or co-authored) 141 research publications.
  • Brian Jonas, MD (ucdavis)
    Associate Professor, Hematology and Oncology. Authored (or co-authored) 58 research publications.


accepting new patients
Start Date
Completion Date
GlycoMimetics Incorporated
Phase 3
Study Type
Last Updated